Your browser doesn't support javascript.
loading
Innovative vaccine approaches-a Keystone Symposia report.
Cable, Jennifer; Rappuoli, Rino; Klemm, Elizabeth J; Kang, Gagandeep; Mutreja, Ankur; Wright, Gavin J; Pizza, Mariagrazia; Castro, Sowmya Ajay; Hoffmann, Joseph P; Alter, Galit; Carfi, Andrea; Pollard, Andrew J; Krammer, Florian; Gupta, Ravindra K; Wagner, Caroline E; Machado, Viviane; Modjarrad, Kayvon; Corey, Lawrence; B Gilbert, Peter; Dougan, Gordon; Lurie, Nicole; Bjorkman, Pamela J; Chiu, Christopher; Nemes, Elisa; Gordon, Stephen B; Steer, Andrew C; Rudel, Thomas; Blish, Catherine A; Sandberg, John Tyler; Brennan, Kiva; Klugman, Keith P; Stuart, Lynda M; Madhi, Shabir A; Karp, Christopher L.
Afiliación
  • Cable J; PhD Science Writer, New York, New York.
  • Rappuoli R; GSK, Siena, Italy.
  • Klemm EJ; Wellcome Trust, Bloomsbury, London, UK.
  • Kang G; Division of Gastrointestinal Sciences, Christian Medical College, Vellore, India.
  • Mutreja A; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID) and Department of Medicine, University of Cambridge, Cambridge, UK.
  • Wright GJ; Cell Surface Signalling Laboratory, Wellcome Sanger Institute, Hinxton, UK.
  • Pizza M; Department of Biology, Hull York Medical School, and York Biomedical Research Institute, University of York, York, UK.
  • Castro SA; GSK, Siena, Italy.
  • Hoffmann JP; Division of Molecular Microbiology, School of Life Sciences, University of Dundee, Dundee, UK.
  • Alter G; Departments of Pediatrics and Medicine, Center for Translational Research in Infection and Inflammation, Tulane University School of Medicine, New Orleans, Louisiana.
  • Carfi A; Ragon Institute of MGH, MIT and Harvard, Harvard Medical School, Cambridge, Massachusetts.
  • Pollard AJ; Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Krammer F; Moderna Inc., Cambridge, Massachusetts.
  • Gupta RK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Oxford, UK.
  • Wagner CE; The Tisch Cancer Institute and Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Machado V; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID) and Department of Medicine, University of Cambridge, Cambridge, UK.
  • Modjarrad K; Africa Health Research Institute, Durban, South Africa.
  • Corey L; Department of Bioengineering, McGill University, Montreal, Quebec, Canada.
  • B Gilbert P; Measles and Respiratory Viruses Laboratory, WHO/NIC, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, Brazil.
  • Dougan G; Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland.
  • Lurie N; Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, Washington.
  • Bjorkman PJ; Department of Medicine, University of Washington School of Medicine, Seattle, Washington.
  • Chiu C; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Nemes E; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Gordon SB; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID) and Department of Medicine, University of Cambridge, Cambridge, UK.
  • Steer AC; Coalition for Epidemic Preparedness Innovations, Oslo, Norway.
  • Rudel T; Harvard Medical School, Boston, Massachusetts.
  • Blish CA; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, California.
  • Sandberg JT; Department of Infectious Disease, Imperial College London, London, UK.
  • Brennan K; Division of Immunology, Department of Pathology, South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
  • Klugman KP; Malawi Liverpool Wellcome Research Programme, Blantyre, Malawi.
  • Stuart LM; Infection and Immunity, Murdoch Children's Research Institute, Parkville, Victoria, Australia.
  • Madhi SA; Department of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia.
  • Karp CL; Department of General Medicine, The Royal Children's Hospital, Melbourne, Victoria, Australia.
Ann N Y Acad Sci ; 1511(1): 59-86, 2022 05.
Article en En | MEDLINE | ID: mdl-35029310
The rapid development of COVID-19 vaccines was the result of decades of research to establish flexible vaccine platforms and understand pathogens with pandemic potential, as well as several novel changes to the vaccine discovery and development processes that partnered industry and governments. And while vaccines offer the potential to drastically improve global health, low-and-middle-income countries around the world often experience reduced access to vaccines and reduced vaccine efficacy. Addressing these issues will require novel vaccine approaches and platforms, deeper insight how vaccines mediate protection, and innovative trial designs and models. On June 28-30, 2021, experts in vaccine research, development, manufacturing, and deployment met virtually for the Keystone eSymposium "Innovative Vaccine Approaches" to discuss advances in vaccine research and development.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 / 4_TD Problema de salud: 1_doencas_nao_transmissiveis / 1_medicamentos_vacinas_tecnologias / 2_cobertura_universal / 2_muertes_prematuras_enfermedades_notrasmisibles / 4_pneumonia Asunto principal: Vacunas contra la Influenza / Vacunas / COVID-19 Límite: Humans Idioma: En Revista: Ann N Y Acad Sci Año: 2022 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 / 4_TD Problema de salud: 1_doencas_nao_transmissiveis / 1_medicamentos_vacinas_tecnologias / 2_cobertura_universal / 2_muertes_prematuras_enfermedades_notrasmisibles / 4_pneumonia Asunto principal: Vacunas contra la Influenza / Vacunas / COVID-19 Límite: Humans Idioma: En Revista: Ann N Y Acad Sci Año: 2022 Tipo del documento: Article